ITM Isotope Technologies Munich and Debiopharm Partner to Develop ITM-91/ITM-94D Theranostic Pair for Solid Tumors
Shots:
- ITM & Debiopharm have partnered as per which ITM secures exclusive worldwide right to develop & commercialize CA IX targeting ITM-91/ITM-94D. Debiopharm will get ~$331.24M (~€300M) upfront, development & regulatory milestones plus commercial milestones & low double-digit sales-based royalties
- The pair is being evaluated under P-I/II (GaLuCi) study in locally advanced ccRCC, PDAC & CRC patients, with part A focusing on the safety & imaging performance of ITM-94D in CA IX-expressing tumors, part B finding escalating doses of ITM-91 in patients with high tracer uptake & part C assessing the safety & efficacy of ITM-91
- ITM-94D ([68Ga] Ga-DPI-4452) is a PET imaging agent used to diagnose cancers overexpressing CA IX, which can then be treated with ITM-91 ([177Lu] Lu-DPI-4452) that delivers targeted radiation for tumor destruction from within
Ref: Debiopharm | Image: ITM Isotope Technologies Munich & Debiopharm
Related News:- BioNTech and OncoC4 Initiate Pivotal P-III Trial of Gotistobart (BNT316/ONC-392) in Patients with Metastatic Non Small Cell Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
